Deals In Depth: September 2019
Executive Summary
Sumitomo Dainippon Pharma paid $3bn up front in a wide-ranging deal involving multiple "vant" companies owned by Roivant. Lundbeck acquired what could be an important asset in the CGRP migraine market with the takeover of Alder for nearly $2bn in up-front and earn-out payments. Device financing surpassed pharma financing due to a $2bn debt offering by Alcon.